Tsis ntev los no, Xinlitai tshaj tawm tias nws tus kheej tsim cov tshuaj tshiab SAL0145 Txhaj (txoj haujlwm code: SALO0145) rau kev kho mob ntawm metabolic dysfunction txuam nrog steatohepatitis (MASH) tau raug lees txais rau daim ntawv thov kuaj mob.
1. General Specification (hauv Tshuag)
(1) API (Ntshiab hmoov)
(2) Cov ntsiav tshuaj
(3) Capsules
(4) Txau
(5) Pill press machine
https://www.achievechem.com/pill-xwm
2.Customization:
Peb yuav sib tham tus kheej, OEM / ODM, Tsis muaj hom, rau kev tshawb nrhiav kev ruaj ntseg nkaus xwb.
PIB: BM-2-4-009
Tirzepatide CAS 2023788-19-2
Lub khw tseem ceeb: Tebchaws Asmeskas, Australia, Brazil, Nyiv, Lub Tebchaws Yelemees, Indonesia, UK, New Zealand, Canada thiab lwm yam.
Chaw tsim tshuaj paus: BLOOM TECH Xi'an Hoobkas
Peb muabtirzepatide hmoov, thov xa mus rau lub vev xaib hauv qab no kom paub meej specifications thiab cov ntaub ntawv khoom.
Khoom siv:https://www.bloomtechz.com/news/peptides-nqi- npe- ntawm-bloom-tech-85355837.html
SALO145 yog ib qho tshuaj me me cuam tshuam nucleic acid (siRNA), thiab cov kev tshawb fawb ua ntej tau pom tias SAL0145 muaj peev xwm kho MASH. Yog tias ua tiav kev tsim kho thiab pom zoo rau kev ua lag luam, nws yuav tsum muab cov neeg mob nrog cov kev xaiv tshuaj tshiab, ua tau raws li cov kev xav tau ntawm cov chaw kho mob tsis zoo, thiab ntxiv dag zog rau lub tuam txhab cov khoom lag luam tshiab hauv cov kab mob ntev. Kev cuam tshuam me me RNA (siRNA) feem ntau yog luv luv ob npaug RNA tsim los ntawm cov khub hauv paus, uas ua tiav qhov tshwj xeeb ntsiag to ntawm cov hom phiaj kab mob mRNA ntawm qib transcriptional los ntawm RNAI mechanism, ua tiav lub hom phiaj ntawm kev kho mob ntawm cov kab mob.
Cov tshuaj SiRNA tuaj yeem tsom cov noob kab mob kom raug thiab muaj qhov zoo ntawm tsis yooj yim tsim cov tshuaj tiv thaiv thiab ntev - ua haujlwm tau ntev. Qhov zaus ntawm kev tswj hwm raug txo qis, txhim kho cov neeg mob ua raws li txoj cai. Nws xav tias yuav rhuav tshem cov tshuaj kho mob ib txwm muaj thiab muaj peev xwm zoo rau kev siv hauv kev kho mob ntev.
Thawj Smeaglutide qhov ntswg tsuag hauv ntiaj teb tau pom zoo hauv Suav teb
Thaum Lub Ib Hlis 12, 2026, CDE lub vev xaib official tau qhia tias Smeaglutide nasal spray tau tshaj tawm los ntawm World Link Pharmaceutical tau pom zoo rau kev siv tshuaj kho mob, uas tsim nyog rau ntev -lub sij hawm tswj qhov hnyav ntawm cov neeg laus raws li kev tswj hwm kev noj zaub mov thiab ua kom lub cev muaj zog.
Thawj lub cev qhov hnyav (BM) tau ntsib cov xwm txheej hauv qab no: Ntau dua lossis sib npaug li 28kg / m2 (kev rog), lossis ntau dua lossis sib npaug ntawm 24kg / m2 rau<28kg/m2 (overweight), and there was at least one droop related complication, such as hyperglycemia, hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease. The registration classification was 2.2.Siluridine from Shiling Pharmaceutical is a nasal spray agent developed based on a mucosal delivery platform, which has the advantages of avoiding first pass effects and improving bioavailability;
Kev tswj hwm tshuaj tsis muaj kev cuam tshuam, kev ua raws cai siab, muaj txiaj ntsig zoo rau kev kho kab mob thiab kev tswj hwm; Kev siv tshuaj yooj yim thiab kev tswj tus kheej.
Thaum Lub Ib Hlis 7, 2026, World Link Pharmaceutical tshaj tawm tias Smeaglutide nasal spray tau pom zoo los ntawm US FDA, uas xav tias yuav dhau los ua daim ntawv thib peb ntawm kev noj tshuaj tom qab txhaj tshuaj thiab npaj qhov ncauj.
Ntxiv nrog rau qhov mucosal tus me nyuam platform, Shiling Pharmaceutical kuj tau tsim lub transdermal tus me nyuam platform. Thaum Lub Kaum Ob Hlis 2024, thawj lub tsev tsim kho thiab cov cuab yeej txawj ntse tsim kho tshiab hloov pauv raws li lub platform no tau pom zoo rau kev siv tshuaj thawj zaug. Nws yog siv raws li kev kho mob monotherapy rau cov neeg mob uas muaj tus kab mob Parkinson thawj zaug thiab hauv kev kho mob nrog levodopa rau cov neeg mob uas muaj qhov hloov pauv ntawm qhov kawg ntawm cov tshuaj.
Saint Yin Biotechnology SGB-7342 (INHBE siRNA) ua tiav thawj zaug kev tswj hwm
Thaum Lub Ib Hlis 13, 2026, Shengyin Biotechnology, lub tuam txhab kho mob theem biotechnology tau tsom mus rau kev txhim kho RNA cuam tshuam (RNA) kho tshiab, tshaj tawm tias nws tus kheej tsim kev cuam tshuam me me RNA (siRNA) tus neeg sib tw tshuaj SGB7342 tau ua tiav thawj zaug kev tswj hwm hauv thawj theem kev sim tshuaj kho mob thawj zaug hauv tsev kho mob hauv Suav teb. Qhov no randomized, ob - dig muag, placebo- tswj, ib koob tshuaj nce ntxiv Phase 1 kev tshawb fawb soj ntsuam lub hom phiaj los ntsuas kev nyab xeeb, kev ua siab ntev, pharmacokinetics, thiab pharmacological yam ntxwv ntawm SGB 7342 hauv cov neeg mob rog rog thiab rog.
SGB-7342 yog siRNA tus neeg sib tw tshuaj tsom rau Inhibin BE subunit (INHBE) rau kev kho mob rog, tsim los siv cov cuab yeej GaINAC coupling xa khoom thiab tshuaj hloov kho tshuab los ntawm Saint Yin Biotechnology. Lub platform thev naus laus zis tau pom tias muaj peev xwm zoo tshaj plaws hauv chav kawm nta hauv theem 1 kev sim tshuaj xyuas ntawm ntau yam tshuaj siRNA hauv kev txhim kho los ntawm lub tuam txhab.
SGB-7342 tshwj xeeb silences cov lus qhia ntawm INHBE noob los ntawm RNA thev naus laus zis, yog li txo cov qib ntawm nws cov protein encoded ActinVvin E thiab ua haujlwm zoo inhibiting downstream signaling txoj kev ua ub no ntsig txog lipid metabolism thiab kev siv zog. Cov kev tshawb fawb hauv tsev kho mob tau pom tias SGB-7342 tuaj yeem ua tau zoo thiab tsis tu ncua INHBE cov lus qhia, txo lub cev qhov hnyav thiab rog, thaum tswj cov leeg nqaij, thiab ua kom pom kev nyab xeeb thiab ua haujlwm ntev.
